Introduction
============

Osteoarthritis (OA) is a prevalent, heritable degenerative joint disease, primarily involving large weight-bearing joints in the hip and the knee ([@B31]; [@B26]). As the most common musculoskeletal disease ([@B24]), OA causes major pain, disability, low quality of life and an increased social healthcare burden globally ([@B5]). A report ([@B22]) investigating 27 million adults found that OA was diagnosed in over 10% of adults and was the fourth most common cause for hospitalization. The World Health Organization Scientific Group estimated that OA caused health issues in 10% of the world population, over 60 years old ([@B35]).

Osteoarthritis is characterized by a complex pathological process including progressive cartilage erosion, osteophyte formation, subchondral bone modification, and synovial inflammation. It involves a long disease span of approximately10 to 20 years from onset to the end-stage, when joint replacement is recognized as the most effective treatment ([@B7]). Therefore, better identification is urgently required. Biomarkers, which are biological molecules that indicate biological processes, could be used for the identification of OA. Previous studies have mainly focused on the gene expression profiles of articular cartilage, meniscus or synovium from progressive OA patients, and the use of the resulting biomarkers for progressive OA is widespread. However, few consensual biomarkers are available for subchondral bone. Currently, accumulative evidence shows that alterations in subchondral bone are associated with the initiation of OA ([@B3]). An analysis of gene expression microarray profiling of subchondral bone samples could contribute to the identification of new biomarkers and increase the mechanistic understanding necessary to provide early prevention and management of OA ([@B33]).

Weighted gene co-expression network analysis (WGCNA), a new systems biology method, is increasingly being used in bioinformatics to analyze gene expression microarray profiling data ([@B29]; [@B37]; [@B16]). By constructing a gene co-expression network, highly correlated genes are clustered into several modules. After relating modules to external information, biologically interesting modules are detected. From interesting modules associated with important biological functions or pathways, critical genes are found which play key roles in the phenotype and the development of disease, such as those involved in body weight ([@B11]), brain cancer ([@B14]), diabetes ([@B15]), and osteoporosis ([@B9]). In addition, WGCNA can be used to screen candidate biomarkers or therapeutic targets. Therefore, we conducted the current study to find new biomarkers, relevant genes or potential mechanisms associated with OA.

Materials and Methods {#s1}
=====================

Data Collection and Preprocessing
---------------------------------

The gene expression profile of OA was downloaded from the Gene Expression Omnibus database ^[1](#fn01){ref-type="fn"}^. The GSE51588 microarray dataset ([@B6]) was obtained from 50 subchondral bone samples including those from 10 non-OA control subjects (five from the lateral tibial plateau and five from medial tibial plateau) and 40 OA subjects (20 from the lateral tibial plateau and 20 from the medial tibial plateau). A series matrix file was preprocessed to find differentially expressed genes based on variance analysis and 5439 genes were obtained for subsequent analysis.

Co-expression Network Construction
----------------------------------

The "WGCNA" package ([@B16]) in R software was used for the network construction. Samples which met the Z.K value \< -2.5 were deemed as outlying and removed from the expression and trait data. The Pearson correlation coefficients were calculated for all gene comparisons. Then, a weighted network adjacency matrix was calculated based on a~ij~ = \| cor (x~i~, x~j~)\|^β^. X~i~ and x~j~ are the nodes i and j of the network and β was determined using a scale-free topology criterion ([@B37]). The adjacency matrix was converted to a topological overlap matrix to identify gene modules, clusters of highly interconnected genes. A topological overlap measure (TOM) was used to determine the network interconnectedness. Gene modules were detected using the hierarchical clustering method based on a TOM-based dissimilarity measure (1-TOM) ([@B25]). The identification of branches of a hierarchical clustering dendrogram was conducted through the dynamic branch cut method ([@B17]).

Identification of Clinically Significant Modules and Functional Annotation
--------------------------------------------------------------------------

Modules from hierarchical clustering with a dense correlation with biological or clinical information were selected as the interesting modules for subsequent analysis. In this process, gene significance (GS), module significance (MS), and module eigengene (ME) were calculated. GS was defined as the minus log of a *p*-value and MS was the average gene significance across the module gene. ME was the first principal component of a given module. The significance between the ME and a clinical trait was also calculated, as modules with a high trait significance were associated with pathways and could be a candidate ([@B11]; [@B10]). Gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment via the database for Annotation, Visualization, and Integrated Discovery ([@B8]), were performed to further validate the selected modules by finding the underlying mechanism and biological pathways.

Identification and Validation of Hub Genes
------------------------------------------

The hub genes of an interesting module were determined through an absolute value of the geneModuleMembership \> 0.9 and a geneTraitSignificance \> 0.2 ([@B13]). All genes from the selected interesting modules were then mapped into a protein--protein interaction (PPI) network using the Search Tool for the Retrieval of Interacting Genes database ([@B30]). The PPI network was visualized using Cytoscape ([@B28]) and genes with more than 10 nodes were chosen for the determination of common components between the interesting module and the PPI network. The gene expression profile GSE57218 from cartilage samples was used to validate some hub genes within the yellow and brown modules through a one-way analysis of variance (*p* \< 0.05).

Results
=======

Data Preprocessing and Co-expression Network Construction
---------------------------------------------------------

Based on variance analysis, the top 25% of genes (5439 genes) was obtained from GSE51588 with 50 samples. As shown in [Figure 1](#F1){ref-type="fig"}, the GSM1248767 sample was outlying. In the current study, the soft-thresholding parameter was determined as β = 12 where the curve first reached Rˆ^2^ = 0.85, to construct a weighted network based on a scale-free topology criterion ([Figure 2](#F2){ref-type="fig"}). As is shown in [Figure 3](#F3){ref-type="fig"}, 19 modules were detected through the dynamic tree cutting method.

![Sample dendrogram and trait heatmap. The leaves of the tree correspond to osteoarthritis (OA) samples and non-steoarthritis (non-OA) samples. The first color band underneath the tree indicates which arrays appear to be outlying. The second color band represents disease stages which indicate OA and non-OA (red indicates high values). The third color band represents tissue sources which indicate samples from knee lateral tibial (LT) and medial tibial (MT) (red indicates high values). Similarly, the remaining color-bands color-code the numeric values of physiologic traits.](fphys-10-00275-g001){#F1}

![Analysis of network topology for various soft-theholding powers. The left panel shows the scale-free fit index, signed Rˆ^2^ (y-axis) and the soft threshold power (x-axis). β = 12 was chosen for subsequent analysis. The right panel shows the mean connectivity (y-axis) is a strictly decreasing function of the power β (x-axis).](fphys-10-00275-g002){#F2}

![Clustering dendrogram of genes. The color bands provide a simple visual comparison of module assignments (branch cuttings) based on the dynamic tree cutting method.](fphys-10-00275-g003){#F3}

Identification of Clinically Significant Modules and Functional Annotation
--------------------------------------------------------------------------

After relating modules to traits, high correlations were observed in the trait of stage (OA or non-OA) and tissue (lateral tibial plateau and medial tibial plateau) ([Figure 4](#F4){ref-type="fig"}). In terms of the trait of stage, the highest correlation was observed in the yellow-stage module (*r* = 0.71, *p* = 1e-08). As for tissue, the brown tissue module had the highest correlation (*r* = 0.77, *p* = 1e-10). Genes in the yellow (cor = 0.5, *p* = 2.9e-27, [Figure 5](#F5){ref-type="fig"}) and brown modules (cor = 0.75, *p* = 8.7e-76, [Figure 6](#F6){ref-type="fig"}) were characterized with high gene significance and module membership, based on an intramodular analysis. [Supplementary Table 1](#SM1){ref-type="supplementary-material"} demonstrates that the yellow module was enriched in a variety of components including proteinaceous extracellular matrix, collagen trimers, endoplasmic reticulum lumen, extracellular regions, collagen catabolic processes, and components involved in osteoblast differentiation, etc., based on GO analysis (*p* \< 0.001). [Supplementary Table 2](#SM1){ref-type="supplementary-material"} shows that the yellow module included genes involved in protein digestion and absorption, axon guidance, ECM-receptor interaction, and the PI3K-Akt signaling pathway, etc. based on KEGG pathway analysis (*p* \< 0.05). The brown module was enriched in components involved in extracellular space, extracellular region, extracellular matrix, cell adhesion, and brown fat cell differentiation, etc. (*p* \< 0.001, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}). In addition, the brown module contained components involved in tyrosine metabolism, drug metabolism (cytochrome P450), ECM-receptor interaction, and the regulation of lipolysis in adipocytes, etc. (*p* \< 0.01, [Supplementary Table 4](#SM1){ref-type="supplementary-material"}). Finally, the yellow module, with 409 genes, and the brown module with 413 genes were deemed as clinically significant modules with associations with OA development.

![Module-trait relationships. Stage indicates OA and non-OA; tissue indicates samples from LT and MT.](fphys-10-00275-g004){#F4}

![Scatter diagram for module membership vs. gene significance of stage (OA or non-OA) in yellow module.](fphys-10-00275-g005){#F5}

![Scatter diagram for module membership vs. gene significance of tissue (LT or MT) in brown module.](fphys-10-00275-g006){#F6}

Identification and Validation of Hub Genes
------------------------------------------

Based on an absolute value of the geneModuleMembership \> 0.9 and geneTraitSignificance \> 0.2, 45 hub genes and 72 hub genes were selected from the yellow module and brown module, respectively ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). These hub genes were mapped into the PPI network. As shown in [Table 1](#T1){ref-type="table"} and [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}, five common genes (COL24A1, COL5A2, COL3A1, MMP2, and COL6A1) were observed in the yellow module and PPI network associated with OA stage. Eight common genes (LIPE, LPL, LEP, SLC2A4, FABP4, ADH1B, ALDH4A1, and ADIPOQ) were observed in the brown module and PPI network associated with OA tissue ([Table 2](#T2){ref-type="table"} and [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). The results of the validation of the hub genes from the yellow and brown modules are displayed in [Supplementary Table 5](#SM1){ref-type="supplementary-material"}.

###### 

Hub genes from the yellow module.

  Probe           Gene        GeneModuleMembership   Hub gene in the PPI network
  --------------- ----------- ---------------------- -----------------------------
  A_23_P253958    LRRC17      0.969473235            No
  A_23_P48198     GLT8D2      0.959877328            No
  A_23_P74701     COL24A1     0.955163023            Yes
  A_23_P56746     FAP         0.946811157            No
  A_33_P3364741   MRC2        0.944254916            No
  A_23_P33196     COL5A2      0.942647924            Yes
  A_24_P211565    C1QTNF6     0.940056543            No
  A_33_P3336700   SHROOM3     0.938124468            No
  A_33_P3222917   CD276       0.936416148            No
  A_33_P3380529   PRTFDC1     0.935426537            No
  A_33_P3280845   THY1        0.934100495            No
  A_24_P935491    COL3A1      0.930260322            Yes
  A_23_P63432     RHBDL2      0.925783098            No
  A_33_P3237135   MMP2        0.923664358            Yes
  A_33_P3336686   CLIC3       0.921127157            No
  A_33_P3260575   CERCAM      0.920273281            No
  A_33_P3398156   CYS1        0.919702463            No
  A_23_P99906     HOMER2      0.918751881            No
  A_23_P151529    C14orf132   0.917087409            No
  A_23_P130194    PYCR1       0.91518196             No
  A_23_P52336     UNC5B       0.914926299            No
  A_24_P167654    SLC8A3      0.91488311             No
  A_33_P3309551   PTPRD       0.91401164             No
  A_24_P74070     PARD6G      0.913560661            No
  A_23_P302787    LOC375295   0.913478286            No
  A_23_P111888    CTHRC1      0.912267336            No
  A_24_P118196    GXYLT2      0.912119625            No
  A_32_P29118     SEMA3D      0.912067684            No
  A_32_P32254     COL6A1      0.911032192            Yes
  A_33_P3360540   AGPAT2      0.910588547            No
  A_24_P408736    GALNT5      0.908471069            No
  A_23_P211504    KDELR3      0.90828204             No
  A_23_P109171    BFSP1       0.907830969            No
  A_23_P251499    PCOLCE      0.907617452            No
  A_23_P101093    COPZ2       0.907504995            No
  A_24_P227927    IL21R       0.906686906            No
  A_23_P69586     FAT1        0.906224666            No
  A_33_P3214159   CDH2        0.905437519            No
  A_24_P827037    LRRC15      0.90472131             No
  A_33_P3345041   FLJ32063    0.904134402            No
  A_24_P215765    ATP10A      0.903870696            No
  A_23_P159907    MAGED4B     0.903422964            No
  A_24_P97825     CCDC69      0.902890892            No
  A_23_P163567    SMPD3       0.901995577            No
  A_23_P53193     SYTL2       0.901980687            No
                                                     

###### 

Hub genes from the brown module.

  Probe           Gene       GeneModuleMembership   Hub gene in the PPI network
  --------------- ---------- ---------------------- -----------------------------
  A_23_P151232    TMEM132C   0.969856283            No
  A_33_P3242543   MAOA       0.963154509            No
  A_33_P3293362   1-Mar      0.961606389            No
  A_23_P64617     FZD4       0.961128123            No
  A_33_P3294986   LIPE       0.960301918            Yes
  A_23_P146233    LPL        0.959713729            Yes
  A_23_P308058    TUSC5      0.956794965            No
  A_33_P3371115   AQP7P3     0.955308305            No
  A_24_P397817    LEP        0.95325835             Yes
  A_23_P39251     PLIN5      0.947555058            No
  A_23_P145786    MLXIPL     0.945273946            No
  A_33_P3240018   PDE3B      0.944749134            No
  A_23_P376704    CIDEA      0.944504899            No
  A_23_P36658     MGST1      0.942865498            No
  A_23_P158041    AQP7       0.942784686            No
  A_23_P26154     PLIN1      0.942169131            No
  A_23_P426305    AOC3       0.942153425            No
  A_24_P484797    CIDECP     0.941562321            No
  A_24_P154037    IRS2       0.941550679            No
  A_24_P224727    CEBPA      0.93772696             No
  A_23_P111402    RSPO3      0.937652396            No
  A_23_P128084    ITGA7      0.934366709            No
  A_33_P3214466   MESP1      0.934126996            No
  A_23_P204736    GPD1       0.931926582            No
  A_33_P3400763   PLIN4      0.931566336            No
  A_33_P3405728   PKP2       0.931320128            No
  A_23_P77493     TUBB3      0.931281047            No
  A_32_P57810     RNF157     0.93118069             No
  A_24_P291658    ADH1A      0.930900109            No
  A_24_P206776    CRYAB      0.930810728            No
  A_23_P381172    MRAP       0.9307345              No
  A_23_P42975     PRKAR2B    0.928552349            No
  A_23_P64721     HCAR3      0.928283637            No
  A_23_P92025     CIDEC      0.927149576            No
  A_23_P85015     MAOB       0.927020575            No
  A_33_P3210488   COL6A3     0.925880431            No
  A_23_P79978     SLC24A3    0.925824615            No
  A_32_P40288     TMEM200A   0.92472156             No
  A_33_P3275702   FMO2       0.924148077            No
  A_23_P74609     G0S2       0.923837665            No
  A_33_P3216933   SIK2       0.923807734            No
  A_23_P125505    PPEF1      0.92380506             No
  A_32_P151263    SLC2A4     0.923412235            Yes
  A_23_P8820      FABP4      0.923354566            Yes
  A_32_P33114     KLB        0.921659613            No
  A_23_P386942    DIRAS1     0.919487688            No
  A_33_P3353737   ADH1B      0.918564725            Yes
  A_23_P81158     ADH1C      0.917832335            No
  A_23_P21324     TWIST2     0.915863824            No
  A_23_P145965    TPST1      0.91578472             No
  A_33_P3401243   OLFML2B    0.915629239            No
  A_23_P170337    ALDH4A1    0.915018976            Yes
  A_23_P101131    GRP        0.914667348            No
  A_23_P134237    RARRES2    0.913437641            No
  A_23_P32165     LHX2       0.913193791            No
  A_23_P408249    PCK1       0.912022648            No
  A_23_P63736     LOC84856   0.909998126            No
  A_23_P253029    BOK        0.909722845            No
  A_23_P55477     ADORA2B    0.909432496            No
  A_23_P109636    LRIG1      0.908001504            No
  A_23_P15876     ALPK2      0.907280117            No
  A_33_P3350374   C10orf58   0.905537789            No
  A_23_P37892     GPT2       0.904170892            No
  A_23_P88404     TGFB3      0.903958589            No
  A_23_P20443     LZTS1      0.903319664            No
  A_33_P3298216   MYO16      0.901721107            No
  A_23_P164047    MMD        0.901691839            No
  A_23_P72668     SDPR       0.901641073            No
  A_23_P101407    C3         0.901610377            No
  A_23_P369237    ADIPOQ     0.900895088            Yes
  A_24_P213950    HEPACAM    0.900550393            No
  A_23_P108075    SLC7A10    0.900280812            No
                                                    

Discussion
==========

Because of the high rates of disability, low quality of life, major pain and the resulting huge economic burden caused by OA ([@B23]), a thorough study of OA, including risk factors, pathological processes, clinical manifestation, diagnosis, treatment, and prevention is particularly essential. In the current study, the WGCNA algorithm ([@B16]) was adopted to explore OA biomarkers and pathological processes in samples of subchondral bone from OA and non-OA subjects.

After data set preprocessing, weighted gene network construction, and module identification, relating modules to traits and functional enrichment, we found that both the yellow and brown modules were associated with the occurrence of OA. Specifically, the yellow module with 45 hub genes played a key role in proteinaceous extracellular matrix, collagen trimers, and collagen catabolic processes, etc. and was highly associated with the formation of extracellular matrix and the development of the skeletal system. Extracellular matrix and collagen secreted by mesenchymal cells in subchondral bone ([@B20]) are important components of cartilage and protect the articular surface from destruction in the early stage of OA ([@B27]). In addition, collagen is also a major component of bone. Therefore, collagen dysfunction could lead to bone and joint disease including OA.COL24A1, COL5A2, COL3A1, COL6A1 are members of the collagen gene family. COL24A1 was reported to play an important role in osteoblast differentiation and bone formation ([@B19]) through theTGF-β/Smads signaling pathway ([@B34]). To the best of our knowledge, COL5A2 has been associated with ischemic heart disease ([@B2]) and the development of cancers, such as bladder cancer ([@B18]), glioblastoma ([@B32]), and gastric cancer ([@B4]), with no evidence for an association with OA. A similar role has been reported for COL3A1 ([@B36]). COL6A1 was demonstrated as a hub gene in OA in a recent study ([@B12]). In the current study, the yellow module contained components involved in protein digestion and absorption, axon guidance, ECM-receptor interaction and the PI3K-Akt signaling pathway. The aforementioned four hub genes also identified in the PPI network could be regarded as real hub genes associated with OA through the ECM-receptor interaction and interaction with the PI3K-Akt signaling pathway.

MMP2, a common component of the yellow and PPI network encodes matrix metallopeptidase 2, which is released by inflammatory cells, contributing to the initiation and progression of OA ([@B1]). Inflammation could directly affect synovial cells and chondrocytes through cytokines which would interfere with the repair of cartilage in OA patients.

To identify the difference between early-stage (lateral tibia) and end-stage (medial tibia) OA, we related the modules to tissue traits and the brown module with 72 hub genes was found to contain genes involved in extracellular processes and lipid metabolism. The GO analysis of the brown module demonstrated enrichment in components involved in the extracellular space, region and matrix, further demonstrating that the destruction of the extracellular matrix leads to the progression of OA. LIPE, LPL, LEP, SLC2A4, FABP4, ADH1B, ALDH4A1, and ADIPOQ are all involved in energy metabolism in subchondral bone cells. It was speculated that end-stage OA was associated with lower energy metabolism, compared with early-stage OA. Therefore, drugs to improve lipid metabolism could prevent OA progression.

The results of the validation demonstrated that COL5A2, COL3A1, and COL6A1 at the core of the yellow module and PPI network were associated with OA in samples collected from cartilage and subchondral bone. Other hub genes validated in the yellow module, including FAP, CD276, PRTFDC1, THY1, RHBDL2, CLIC3, CERCAM, CYS1, and HOMER2 had significant differences between OA and non-OA subjects and CD276 has been reported as a biomarker for OA in a previous study ([@B21]). In the brown module, significant validation results were observed for FZD4, TUSC5, PDE3B, LIPE, LEP and SLC2A4 genes, of which, LIPE, LEP, and SLC2A4 were at the core of the module and PPI network. Although several hub genes did not demonstrate significant results in the GSE57218 validation, it is noted that these hub genes are still potentially associated with OA, because GSE57218 was obtained using cartilage samples rather than subchondral bone.

There are several highlights in the current study. Firstly, previous studies explored OA pathological processes and biomarkers using cartilage samples. Currently, few studies have focused on subchondral bone. An expression profile of subchondral bone could contribute to a comprehensive understanding of OA and provide more evidence to elucidate the initiation site of OA (bone or cartilage). Secondly, WGCNA has a particular advantage in processing gene expression datasets and the results of this study not only confirmed the findings of previous studies, but also provided new biomarkers for the further study of OA. However, the current study also possesses several limitations. Cartilage samples were used in the validation of hub genes in this study. These hub genes remain to be validated using subchondral bone samples in further studies.

Conclusion
==========

In the current study, we applied the WGCNA algorithm to process gene expression datasets and devised a yellow module with 45 hub genes and a brown module with 72 hub genes associated with OA. Compared with early-stage OA, the brown module revealed that the subchondral bone cells of end-stage OA had lower lipid metabolism. Drugs designed to target these hub genes could prevent the progression of OA.

Author Contributions
====================

H-YG, R-XW, CZ, and MY conceived and designed the study. R-XW, H-YG, L-LL, and YL performed the analysis procedures. JG, R-XW, L-LL, CZ, and YL analyzed the results. YL, L-LL, MY, and JG contributed to analysis tools. R-XW, H-YG, and CZ contributed to the writing of the manuscript. All authors reviewed the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)

Supplementary Material
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphys.2019.00275/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Brian James Morris, The University of Sydney, Australia

[^2]: Reviewed by: Rushita Bagchi, University of Colorado Denver, United States; Giovanna Calabrese, Università degli Studi di Catania, Italy

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology
